Industry Trend Analysis
In 2014, the global next-generation sequencing market was evaluated around USD 2.82 billion and is expected to reach approximately USD 15.04 billion by 2023 while registering itself at a compound annual growth rate (CAGR) of 20.43% over the forecast period. Expansion of more rapid and efficient genomic sequencing methodologies is projected to fuel the NGS platforms adoption further and consequently regulating industrial expansion. Rising automation within the pre-sequencing protocols is projected to boost progress in the global industry in the approaching years. Use of innovative platforms for the growth of custom-made medicine by clinical analysis at a genetic stage is a major factor that is likely to improve NGS demand during the forecast years. An escalating amount of R&D projects in the areas of transcriptomics, metabolomics, and proteomics are anticipated to fuel the technology demand as well. Genomics and proteomics function with and on a massive array of structural data that demands to be accumulated and classified through subsequent integrated data analysis and sequence determination. The introduction of novel services and products by well-known market giants is anticipated to boost the growth during the forecast years. Additionally, growing inclination of drug developers and scientists for the NGS technology in an attempt to employ the avenues of tailored medicine has established to be a high rise for demanding these platforms with the aim of gaining penetrations into the genetic enterprises of a huge amount of organisms. This augments in demand is expected to boost the NGS industry over the forecast period.
Application Outlook and Trend Analysis
Application-wise NGS technology has profitable approaches in preimplantation and prenatal genetic screening, developmental oncology, HLA typing/immune system monitoring, epidemiology & drug development, metagenomics, agrigenomics & forensics, clinical investigation, and consumer genomics. Oncology is expected to demonstrate profitable growth in the approaching years owing to the speedily developing of sequencing capabilities that facilitate directed sequence determination of an amount of cancer genes that allow oncologists to acquire genetic data exist in few of the less available dense gene clusters concerning cancer tumors and cells.
Technology Outlook and Trend Analysis
Targeted sequencing reported for the leading share due to the existence of numerous benefits linked with a minor dataset and decline in sequencing prices. Moreover, expansion in the amount of protein expression analysis projects is projected to rise due to the existence of DNA-based sequence data sets. Whole genome sequencing (WGS) includes de novo genome, microbial, and genome applications. It is anticipated to observe top year on year growth due to an amplified amount of research programs focused at mapping non-human and human whole genomes joint with decreasing WGS costs.
Work flow Outlook and Trend Analysis
In 2015, sequencing ruled in terms of market revenue share and is anticipated to maintain its supremacy over the projected period. Subsequent to this step, data analysis is projected to experience major growth than rest steps of workflow due to the existence of extensive activities for development and upgradation of novel algorithms in an attempt to render rapid outcome following data analysis.
End User Outlook and Trend Analysis
Usage of these solutions in R&D projects that are executed in the research centers and universities are prenominal for the leading share due to the existence of a huge amount of R&D projects. On-site bioinformatics courses provision which includes the workshops on the actual implementation of data analysis and NGS are also anticipated to fuel revenue produced via academic research in the approaching years. Rising NGS-based smaller scale platforms’ adoption for medical diagnostics is also a major end market projected to fuel demand during the future.
Regional Outlook and Trend Analysis
In 2015, North American regional NGS market reported for the leading share. This huge share can be reported for the existence of an improved technological medical framework, rising adoption of declining in the price of sequencing for each base pair, and elevated R&D funding for proteomic and genomic sequence determination for research of biomarkers. Also, most of the respondents for clinical & academic use are situated in the UK, U.S., and Germany due to the existence of numerous universities that present courses for molecular biology in the region thus affecting the expansion of NGS industry in European and North American regional market. Asia Pacific region is anticipated to grow at the leading rate with a compound annual growth rate of around 18% over the forecast years due to escalating investment for escalating healthcare awareness levels of the regional population, development of healthcare, and escalating residual and per capita income levels.
Competitive Outlook and Trend Analysis
The major market players in global next-generation sequencing market are Beijing Genomics Institute, Pacific Biosciences, Knome Inc., F Hoffmann-La Roche, Thermo Fisher Scientific, GATC Biotech AG., Oxford Nanopore Technologies Inc., Biomatters Ltd., Agilent Technologies Inc., DNAStar Inc., Helicos BioSciences, CLC Bio (Qiagen), Macrogen Inc., and Illumina Inc. The rivalry between market players seeking to achieve a grip in the rapidly-developing biotech segment is engaging on numerous battlefields. Companies are concentrating on the advent of economical sequencing devices in regular healthcare checkups.
The global next generation sequencing market is segmented as follows –
Non-Communicable / Other Diseases
HLA Typing/Immune System Monitoring
Metagenomics, Epidemiology & Drug Development
Agrigenomics & Forensics
Targeted Sequencing Analysis
DNA Based Targeted Sequencing Analysis
RNA Based Targeted Sequencing Analysis
Whole Genome Sequencing
Whole Exome Sequencing
By Work flow
NGS Library Preparation Kits
NGS Semi-Automated Library Preparation
NGS Automated Library Preparation
Primary Data Analysis
Secondary Data Analysis
Tertiary Data Analysis
By End User
Hospitals & Clinics
Pharma & Biotech Entities
Rest of Europe
Rest of Asia Pacific
Rest of the World
United Arab Emirates
Some of the key questions answered by the report are:
· What was the market size in 2014 and forecast from 2015 to 2023?
· What will be the industry market growth from 2015 to 2023?
· What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
· What are the major segments leading the market growth and why?
· Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?